Skip to main content

Table 2 Demographic and clinicopathological variables of 330 patients with operated stage III colon cancer in the standard, modified and unfinished XELOX group

From: Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience

Variables Standard XELOX
(n = 126, %)
Modified XELOX
(n = 84, %)
Unfinished XELOX
(n = 120, %)
P value 1 P value 2
Age (years)     0.762 0.454
 ≤ 60 85 (67.5) 59 (70.2) 78 (65.0)   
 > 60 41 (32.5) 25 (29.8) 42 (35.0)   
Gender     1.000 0.386
 Male 69 (54.8) 46 (54.8) 74 (61.7)   
 Female 57 (45.2) 38 (45.2) 46 (38.3)   
BMI (kg/m2)     0.371 0.439
 < 18.5 12 (9.5) 6 (7.1) 14 (11.7)   
 18.5–25.0 83 (65.9) 63 (75.0) 81 (67.5)   
 > 25.0 31 (24.6) 15 (17.9) 25 (20.8)   
Tumor size (cm)     0.945 0.885
 ≤ 4 77 (61.1) 52 (61.9) 73 (60.8)   
 > 4 49 (38.9) 32 (38.1) 47 (39.2)   
Tumor location     0.382 0.567
 Right-sided colon 43 (34.1) 34 (40.5) 54 (45.0)   
 Left-sided colon 83 (65.9) 50 (59.5) 66 (55.0)   
Tumor differentiation     0.751 0.536
 Well/moderately differentiated 91 (72.2) 63 (75.0) 84 (70.0)   
 Poor/undifferentiated 35 (27.8) 21 (25.0) 36 (30.0)   
T stage     < 0.001 < 0.001
 T1–2 7 (5.6) 1 (1.2) 8 (6.7)   
 T3 72 (57.1) 23 (27.4) 61 (50.8)   
 T4 47 (37.3) 60 (71.4) 51 (42.5)   
Numbers of resected lymph nodes     0.145 0.433
 < 12 27 (21.4) 26 (31.0) 31 (25.8)   
 ≥ 12 99 (78.6) 58 (69.0) 89 (74.2)   
N stage     0.541 0.438
 N1 90 (71.4) 56 (66.7) 87 (72.5)   
 N2 36 (28.6) 28 (33.3) 33 (27.5)   
Preoperative serum CEA (ng/mL)     0.063 0.657
 ≤ 5 67 (53.2) 56 (66.7) 76 (63.3)   
 > 5 59 (46.8) 28 (33.3) 44 (36.7)   
Preoperative serum CA19-9 (U/mL)     0.275 0.092
 ≤ 24 86 (68.3) 64 (76.2) 78 (65.0)   
 > 24 40 (31.7) 20 (23.8) 42 (35.0)   
Risk stratification     0.002 0.008
 Low risk 58 (46.0) 21 (25.0) 52 (43.3)   
 High risk 68 (54.0) 63 (75.0) 68 (56.7)   
  1. XELOX oxaliplatin and capecitabine regimen, BMI body mass index, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9
  2. Right-sided colon cancer included the cecum, ascending colon, hepatic flexure, and transverse colon cancer, whereas left-sided colon cancer included the splenic flexure, descending colon, and sigmoid colon cancer. P value 1 is the result of comparing the standard XELOX regimen group with the modified XELOX regimen group. P value 2 is the result of comparing the unfinished XELOX regimen with the modified XELOX regimen group